Actinogen Medical (ASX:ACW’) has announced the appointment of Mr Jeff Carter as its new chief financial officer (CFO).
The company said the appointment reflects its focus on progressing and expanding its clinical development pipeline. It said it will enable for more robust, integrated and strategic financial support.
Mr Carter is an experienced ASX-listed company CFO with a broad corporate background and a significant understanding of the biotechnology sector.
The company said Mr Carter currently holds, and will continue to hold, a part-time position as CFO for Amplia Therapeutics (ASX:ATX).
He has held positions in various biotechnology companies and major corporates in other sectors.
Actinogen CEO and managing director Dr Bill Ketelbey said, “We are delighted that Jeff is joining Actinogen at this exciting time. The appointment comes as we progress towards our next series of clinical trials, with plans to commence multiple studies in the near-to-medium term.
"Jeff will be a valuable addition to the team, with strong corporate experience and a proven track record as CFO for other ASX-listed biotech companies with the capability to build and implement strategic approaches in a range of relevant business activities. We look forward to the broader skills and experience he brings to the senior management team.”